Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

被引:413
作者
Öberg, K
Kvols, L
Caplin, M
Delle Fave, G
de Herder, W
Rindi, G
Ruszniewski, P
Woltering, EA
Wiedenmann, B
机构
[1] Univ Uppsala Hosp, Dept Endocrine Oncol, SE-75185 Uppsala, Sweden
[2] Med Klin MS, Dept Gastroenterol & Hepatol, Berlin, Germany
[3] Louisiana Univ, Hlth Serv Ctr, New Orleans, LA USA
[4] Hosp Beaujon, Serv Gastroenterol, Clichy, France
[5] Univ Panua, Sez Anat, Dept Patol & Med, Lab, Panua, Italy
[6] Erasmus MC, Dept Internal Med, Sect Endocrinol, Rotterdam, Netherlands
[7] Univ Roma La Sapienza, Osped St Andrea, Sch Med 2, Rome, Italy
[8] Royal Free Hosp, Ctr Gastroenterol, London NW3 2QG, England
[9] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
关键词
gastroenteropancreatic system; lanreotide; neuroendocrine tumors; octreotide; somatostatin; somatostatin analogs; tumor markers; imaging;
D O I
10.1093/annonc/mdh216
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This consensus report gives a detailed description of the use of somatostatin analogs in the management of neuroendocrine tumors of the gastroenteropancreatic system. As background information we have outlined critical aspects of the pathology, the use of tumor markers, a definition of functional and non-functional digestive neuroendocrine tumors, different imaging modalities, surgical considerations, liver embolization and the use of cytotoxic drugs as well as interferon. Included in the report is an overview of somatostatin, somatostatin analogs and its receptor expression in different neuroendocrine tumors. It will also define the binding affinities of different somatostatin analogs to the five different subtypes of somatostatin receptor. We compare the efficacy of octreotide and lanreotide in reducing diarrhea and flushing. Side-effects are described and we provide practical information on somatostatin analog treatment.
引用
收藏
页码:966 / 973
页数:8
相关论文
共 57 条
[1]   Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zolinger-Ellison syndrome [J].
Alexander, HR ;
Fraker, DL ;
Norton, JA ;
Bartlett, DL ;
Tio, L ;
Benjamin, SB ;
Doppman, JL ;
Goebel, SU ;
Serrano, J ;
Gibril, F ;
Jensen, RT .
ANNALS OF SURGERY, 1998, 228 (02) :228-238
[2]  
Anderson MA, 2000, AM J GASTROENTEROL, V95, P2271
[3]  
Angeletti S, 1999, ITAL J GASTROENTEROL, V31, P23
[4]   Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies [J].
Anthony, LB ;
Woltering, EA ;
Espenan, GD ;
Cronin, MD ;
Maloney, TJ ;
McCarthy, KE .
SEMINARS IN NUCLEAR MEDICINE, 2002, 32 (02) :123-132
[5]   Treatment of neuroendocrine GEP tumours with somatostatin analogues - A review [J].
Arnold, R ;
Simon, B ;
Wied, M .
DIGESTION, 2000, 62 :84-91
[6]   Intractable hypercalcemia due to a metastatic carcinoid secreting parathyroid hormone-related peptide and interleukin-6: Response to octreotide [J].
Barhoum, M ;
Hutchins, L ;
Fonseca, VA .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1999, 318 (03) :203-205
[7]  
BAUER W, 1982, LIFE SCI, V31, P1133, DOI 10.1016/0024-3205(82)90087-X
[8]  
Behrns K E, 1994, Adv Surg, V27, P233
[9]  
BORDI C, 2004, IN PRESS CURR DIAGN
[10]   SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile [J].
Bruns, C ;
Lewis, I ;
Briner, U ;
Meno-Tetang, G ;
Weckbecker, G .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 146 (05) :707-716